

ACCELERATED COMMUNICATION

Molecular Cloning of a Mammalian Serotonin Receptor that Activates Adenylate Cyclase

JEAN-LUC PLASSAT, NOURDINE AMLAIKY, and RENÉ HEN

Laboratoire de Génétique Moléculaire des Eucaryotes du CNRS, U/184 de l'INSERM, Département de Neurobiologie, Faculté de Médecine, 67085 Strasbourg Cedex, France

Received April 26, 1993; Accepted June 3, 1993

SUMMARY

Serotonin modulates a wide range of physiological functions by activating multiple receptors, which are coupled to various effector systems. Using a strategy based on amino acid sequence homology between 5-hydroxytryptamine (5-HT) receptors, we have isolated from a mouse brain library a cDNA encoding a new 5-HT receptor, 5-HT_x, that activates adenylate cyclase. Amino acid sequence comparisons revealed that the 5-HT_x receptor was a distant relative of previously cloned 5-HT receptors, with the highest percentage of homology (42%) being with the 5-HT₆ receptor, a *Drosophila* 5-HT receptor positively coupled to adenylate cyclase. In COS-7 cells transiently expressing the 5-HT_x receptor, 5-HT induced an increase in cAMP levels that was dose dependent and saturable (EC₅₀ = 45 nM). Agonists displayed the following rank order of potencies: 5-carboxamidotryptamine > 5-methoxytryptamine > 5-HT > RU 24969 > 8-hydroxy-2-(di-*n*-propylamino)tetralin. The most efficient antago-

nists in inhibiting the stimulatory effect of 5-HT were methysergide, methiothepin, mesulergine, metergoline, clozapine, ergotamine, and (+)-butaclamol. Membranes of COS-7 cells expressing the 5-HT_x receptor displayed a single saturable binding site for [³H]5-HT. The order of potencies of various drugs in displacing [³H]5-HT binding was similar to the order obtained in cAMP experiments. The pharmacological profile of this receptor does not correspond to the profile of any of the classic 5-HT receptor subtypes. Expression of 5-HT_x mRNA was highest in brainstem and lower in forebrain, cerebellum, intestine, and heart. The 5-HT_x receptor might therefore correspond to 5-HT₁-like receptors that have been shown to induce relaxation in porcine vena cava and guinea pig ileum as well as tachycardia in cat heart. The high affinity of the 5-HT_x receptor for neuroleptic agents such as (+)-butaclamol and clozapine suggests also that this receptor might play a role in certain neuropsychiatric disorders.

Serotonin is involved in a wide range of behaviors (1), and serotonergic drugs are used in the treatment of a number of pathological states, such as depression, appetite disorders, and migraines (2). Pharmacological studies and molecular cloning identified several subtypes of receptors with distinct pharmacological properties, signaling systems, and tissue distributions (for review, see Refs. 3 and 4). The 5-HT receptors can be classified into two groups, i.e., G protein-coupled receptors, including the 5-HT₁, 5-HT₂, 5-HT₄, and 5-HT₅ receptors, and ligand-gated ion channels, such as the 5-HT₃ receptors. The 5-HT₁ receptors can be further subdivided in 5-HT_{1A} (5), 5-HT_{1B} (6, 7), 5-HT_{1D α} and 5-HT_{1D β} (8), 5-HT_{1E} (9, 10), and 5-HT_{1E β} (also called 5-HT_{1F}) (11, 12) subtypes. The 5-HT₂ family contains the 5-HT₂ (13), 5-HT_{1C} (14), and 5-HT_{2F} (15) subtypes. When expressed in various mammalian cell lines the 5-HT₁

receptors inhibit adenylate cyclase activity, whereas the 5-HT₂ receptors activate phospholipase C. The 5-HT_{6A} and 5-HT_{6B} receptors define a new family of receptors that do not interact with adenylate cyclase or phospholipase C and do not correspond to classical pharmacological subtypes (16, 17). Concerning 5-HT receptors that stimulate adenylate cyclase, there are a number of reports describing a serotonin-sensitive cyclase in membranes from various organs (for review, see Ref. 18). In particular, a receptor termed 5-HT₄ has been found in colliculi and hippocampal neurons as well as in peripheral organs (for review, see Ref. 19). Two 5-HT receptors that activate adenylate cyclase have been cloned so far, the *Drosophila* 5-HT₆ receptor (20) and a recently cloned receptor tentatively called 5-HT₆ (21). However, none of these receptors displays a pharmacological profile that resembles the profile of the 5-HT₄ receptor.

To isolate additional 5-HT receptors, including possibly the 5-HT₄ receptor, we took advantage of the amino acid sequence

This work was supported by grants from CNRS, INSERM, and Rhône-Poulenc Rorer.

ABBREVIATIONS: 5-HT, 5-hydroxytryptamine; 5-CT, 5-carboxamidotryptamine; 5-MeOT, 5-methoxytryptamine; RU 24969, 5-methoxy-3-(1,2,3,6-tetrahydropyridin-4-yl)-1*H*-indole; 8-OH-DPAT, 8-hydroxy-2-(di-*n*-propylamino)tetralin; LSD, lysergic acid diethylamide; TFMPP, 1-(3-trifluoromethylphenyl)piperazine; PCR, polymerase chain reaction; bp, base pair(s); Gpp(NH)_p, guanosine-5'-(β -imidotriphosphate).




Fig. 1. Nucleotide sequence of the 5-HT_x cDNA. The 3.2-kilobase *EcoRI*-*XhoI* cDNA fragment was sequenced on both strands from the *EcoRI* site to position 1539. The remaining 1700 nucleotides were not sequenced. The seven putative transmembrane domains are boxed and numbered (I to VII). Arrows, sites of potential N-linked glycosylation. Circles and triangles, consensus sites for phosphorylation by protein kinase C and protein kinase A, respectively. An in-frame stop codon upstream of the ATG is underlined. *, Terminal stop codon. EMBL/GenBank accession number: Z23107.

homologies found in transmembrane domains 3, 6, and 7 of 5-HT receptors. A reverse PCR was performed on RNA prepared from mouse colliculi neurons and the PCR fragments were used to screen a mouse brain cDNA library. One of the resulting cDNAs was shown to encode a functional 5-HT receptor. Sequence comparisons revealed that this receptor is a new member of the G protein-coupled receptor family that is most homologous (42% amino acid identity) to the 5-HT_{dr1} receptor. When expressed in COS-7 cells, like the 5-HT_{dr1} receptor our new receptor stimulated adenylate cyclase activity. We therefore named it 5-HT_x, while awaiting a final nomenclature. In addition, the 5-HT_x receptor displayed a high affinity for [³H] 5-HT, and its pharmacological profile did not correspond to that of any known serotonin receptor subtype, including the 5-HT₄ receptor and the recently cloned 5-HT₅ and 5-HT₆ receptors. Our results therefore reveal an unexpected heterogeneity among 5-HT receptors that are positively coupled to adenylate cyclase. Interestingly, the 5-HT_x receptor had a high affinity for psychotropic drugs such as clozapine, raising the possibility that this receptor plays a role in neuropsychiatric disorders involving the serotonergic system.

Materials and Methods

Isolation and sequencing of the 5-HT_x cDNA. A doubly nested PCR experiment was performed with the following oligonucleotides: (i) (C/G)(T/A)(A/G)TTG(A/G)C(A/G)TAGCC(C/A)A(A/G/T)CCA, (ii) CTTGATATCGAATTCGA(T/C)(A/G)T(A/G/C/T)CT(A/G/C/T)TG(C/T)TG(C/T)AC, (iii) GGTATCGATAAGCTTAT(C/T/A)GC(C/T)CT(A/G/C/T)GA(C/T)(C/A)G(A/G/C/T)TA, and (iv) AGAACTAGTGGATCCAA(A/G)AA(A/G/C/T)GG(A/G/C/T)A(A/G)CCA(A/G)CA. Five micrograms of total RNA from mouse embryonal colliculi neurons were reverse transcribed in the presence of 1 μg of oligonucleotide i and 12 units of avian myeloblastosis virus reverse transcriptase (Pharmacia). One half of that reaction was then amplified for 30 cycles in the presence of *Thermus aquaticus* polymerase (5 units; Cetus) and oligonucleotides i and ii (1 μg of each). One twentieth of that reaction was amplified for 30 cycles with oligonucleotides i and iii. The resulting products were size selected between 300 bp and 700 bp on a 2% agarose gel. Finally, one fourth of the material extracted from the gel was amplified for 30 more cycles with oligonucleotides iii and ii. Two discrete fragments were obtained, 500 bp and 700 bp long. These fragments were digested with *Bam*HI and *Hind*III, inserted in the Bluescript plasmid, and sequenced. The 500-bp fragment exhibited homology with 5-HT receptors. It was labeled by random priming and

		I		II	
5-HT _x	mouse (87)	-GSI	LTLLTLLTIAGNCLVVISVCFVKNVRQPSNYL	LVSLALADLSVAVAVMVFVSVTDLIGGK	-WIFGHFCNV
5-HT _{dro1}	(165)	-SIV	LLIVILGTIVGNVIVCIACVMVRKERRPCNYL	LVSLALSDLCVAILVMPMALLYEVLE	-K-WNFGPIICDI
5-HT _{1B}	mouse (48)	-VAL	LALITLATTLSNAFVIATVYRTRKHTPANL	IASLA/TDLLVSI/LVMP/ISTMYT-VTGR	-WILGQVVCDF
5-HT _{1Dα}	human (41)	-AVV	LSVITLATVLSNAFVLTITLLTRKHTHPANYL	IGSLA/TDLLVSI/LVMP/ISIAYT-ITHT	-WNSGQITICDI
5-HT _{1A}	human (39)	-SLL	LGTLIFCAVLGNACVVAIALERSIQNVANYL	IGSLA/TDLMVSV/LVMP/MAALYQ-VLNK	-WILGQVVCDF
5-HT _{dro2A}	(229)	-SVL	LGLMLVITIGNVFVIAAILERNLQNVANYL	VASLA/VADLFVAC/LVMP/LGAVYE-ISQG	-WILGPELCDI
5-HT _{dro2B}	(80)	-AVV	LGLMLVITIGNVFVIAAILERNLQNVANYL	VASLA/VADLFVAC/LVMP/LGAVYE-ISNG	-WILGPELCDI
5-HT _{1Eα}	human (25)	-CMT	LAVITITLLTNLAVIMAIGTKKLPANYL	ICSLA/TDLVAV/LVMP/LSIYI-VMGR	-WILGPELCDI
5-HT _{1Eβ}	mouse (26)	-SLT	LSGLALMTTINSLVIAAILVTRKHPANYL	ICSLA/TDLVAV/LVMP/FSIYI-VRES	-WINGQVVCDF
5-HT _{5A}	mouse (43)	-LTL	LGFLAAATFTWNLVLAITLKVTRFHRVPHN	LVASLAISDVIVAV/LVMP/LSLVHLS-GRW	-WILGPELCDI
5-HT _{5B}	mouse (55)	-VTL	LVLIAATFLWNLVLAITLKVTRFHRVPHN	LVASLAISDVIVAV/LVMP/LSLVHLS-GRW	-WILGPELCDI
5-HT _{1C}	rat (57)	-ALS	IVVITITLLTNLAVIMAIGTKKLPANYL	ICSLA/TDLVAV/LVMP/LSIYI-VMGR	-WILGPELCDI
5-HT ₂	rat (77)	-ALL	TTVVITLTIAGNCLVVISVCFVKNVRQPSNYL	LVSLALADLSVAVAVMVFVSVTDLIGGK	-WIFGHFCNV
5-HT _{2F}	rat (56)	-ALL	FAVITITLLTNLAVIMAIGTKKLPANYL	ICSLA/TDLVAV/LVMP/LSIYI-VMGR	-WILGPELCDI
5-HT ₆	rat (30)	-AA	-LCVVIVLTAAANSLIVLICTPAVRNTS	NFFLVSLFTSDLMVGLVMP/PAMLNLY--GRW	-WILGPELCDI
		III		IV	
5-HT _x	mouse	FIAM	DVMCTASIMTLVVISIDRYLGITRPLTY	FPVRQNGKCMAMK	ULSVWPLSASITLPFL-FGW-AQNVNDK
5-HT _{dro1}		WVSF	DVLCCTASILNLCAISVDRIYLAITPLEY	GVKRTPRRMLCVGVVWLAACISLPPL	-LIL-GNEHEDEE
5-HT _{1B}	mouse	WLS	DICTCTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT _{1Dα}	human	WLS	DICTCTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT _{1A}	human	FIAL	DVLCCTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT _{dro2A}		WTS	CDVLCCTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT _{dro2B}		WTS	CDVLCCTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT _{1Eα}	human	WLS	DICTCTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT _{1Eβ}	mouse	WLS	DICTCTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT _{5A}	mouse	WTS	CDVLCCTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT _{5B}	mouse	WTS	CDVLCCTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT _{1C}	rat	WIS	LDVLFSTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT ₂	rat	WIS	LDVLFSTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT _{2F}	rat	WIS	LDVLFSTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
5-HT ₆	rat	WIS	LDVLFSTASIMHLCVIALDRYNAITDAVE	YSKRTPKRAAIMIVVWFSISISLPPL	-F-WR-QA-KAEE
		V			
5-HT _x	mouse	---	VCLISQD-FG-YTIYSTAVAFYIEMSVLMFYQIYKAARKSAKH	-(39)-	RKNIS-SFKREOKKAT
5-HT _{dro1}		GQPI	CTVCQN-FA-YQIYATLGSEYIPLSVMLFVYQIFRAARIVLEE	-(83)-	KKLRF-QLAKEKKAST
5-HT _{1B}	mouse	EMLD	CFVNTDHLV-YTVYSTVGAFYIPLTLLILYGRIFYEARSRLKQ	-(57)-	EKKKL-MAARERKATK
5-HT _{1Dα}	human	EMSD	CLVNTSQIS-YTIYSTCCAFYIPLTLLILYGRIFYEARSRLKQ	-(55)-	ERKRI-SAARERKATK
5-HT _{1A}	human	DPDA	CTISKDH-G-YTIYSTFGAFYIPLTLLILYGRIFYEARSRLKQ	-(101)-	AKRKM-ALARERKIVK
5-HT _{dro2A}		EQQK	CMVSQD-VS-YQVFATCCTFVYVPLMVILALYWKIYQTAARKRIHR	-(316)-	RKETL-EAKREKKAOK
5-HT _{dro2B}		EEQH	CMVSQD-VG-YQVFATCCTFVYVPLMVILALYWKIYQTAARKRIHR	-(235)-	RRQLL-EAKREKKAOK
5-HT _{1Eα}	human	PPSQ	CTIQHDHVI-YTIYSTLGAFYIPLTLLILYGRIFYEARSRLKQ	-(60)-	ERQQT-SSTRERKKAOK
5-HT _{1Eβ}	mouse	RDDE	VIKHDHIV-STIYSTFGAFYIPLTLLILYGRIFYEARSRLKQ	-(63)-	RRQKI-SGTRERKKAOK
5-HT _{5A}	mouse	EE--	CQVSREP-S-YTVFSTVGAFYIPLTLLILYGRIFYEARSRLKQ	-(35)-	TEGDTWREKKEOKAAL
5-HT _{5B}	mouse	QR--	CQVSREP-S-YTVFSTVGAFYIPLTLLILYGRIFYEARSRLKQ	-(35)-	TEGDTWREKKEOKAAM
5-HT _{1C}	rat	NNTT	CVLNPD--NFVLIGSFVAFIPLTIMVITYFLTIKSLQKEATLC	-(50)-	LSGTQAINNEKKASK
5-HT ₂	rat	KEGS	CLLADD--NFVLIGSFVAFIPLTIMVITYFLTIKSLQKEATLC	-(41)-	GRKTMKSISMEOKACK
5-HT _{2F}	rat	HNIT	CELTDRFGSFMFGSLAFAPIITIMVITYFLTIKSLQKEATLC	-(57)-	GKKPAQTISNEOKASK
5-HT ₆	rat	APGQ	QRL-LASLP-FVLVASGVTFLESGAICFTYCRILLAARKQAVQV	-(30)-	RRLATKHSRKALKASL
		VI		VII	
5-HT _x	mouse	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{dro1}		T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{1B}	mouse	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{1Dα}	human	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{1A}	human	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{dro2A}		T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{dro2B}		T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{1Eα}	human	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{1Eβ}	mouse	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{5A}	mouse	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{5B}	mouse	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{1C}	rat	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT ₂	rat	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT _{2F}	rat	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)
5-HT ₆	rat	T	LGIIIVGAFIVCWIPFFILLSTARPFICGTSCS-CIPLWVERTCLWLGYNLSNLINP	ITYSFFNRDLRTTYRSL	-(46)

Fig. 2. Amino acid similarity between the 5-HT_x receptor and other 5-HT receptors. The amino acid sequences of the mouse 5-HT_x receptor and the *Drosophila* 5-HT_{dro1} (20), mouse 5-HT_{1B} (7), human 5-HT_{1Dα} (8), human 5-HT_{1A} (5), *Drosophila* 5-HT_{dro2A} and 5-HT_{dro2B} (38), human 5-HT_{1Eα} (9), mouse 5-HT_{1Eβ} (recently named 5-HT_{1F}) (11), mouse 5-HT_{5A} (16) and 5-HT_{5B} (17), rat 5-HT_{1C} (recently named 5-HT_{2C}) (14) and 5-HT₂ (recently named 5-HT_{2A}) (13), rat stomach fundus 5-HT_{2F} (recently named 5-HT_{2B}) (15), and rat 5-HT₆ (21) receptors were aligned. Numbers in parentheses, number of amino acids that are not represented. Putative transmembrane domains are indicated (I to VII).

A

[illegible]

B




Fig. 3. A, Percentages of amino acid homology between the 5-HT₁ receptor and other 5-HT receptors. These percentages of homology were calculated over the sequences that are represented in Fig. 2. B, Dendrogram. The sequences of the 5-HT receptors were compared and clustered with the program CLUSTAL (39). The lengths of the *horizontal lines* are inversely proportional to the percentages of homology between receptors or groups of receptors.

used to screen a mouse brain cDNA library constructed in the Uni-Zap phage (Stratagene). Positive phages were isolated, and the cDNA inserts were recovered in the Bluescript plasmid and sequenced on both strands by the dideoxynucleotide technique, using successive synthetic oligonucleotides.

Expression of the 5-HT₂ receptor in COS-7 cells. The *EcoRI*-*XhoI* cDNA fragment (Fig. 1) was inserted between the *EcoRI* and *XhoI* sites of expression vector p513, which is a derivative of pSG5 (22) containing a multiple cloning site. The resulting recombinant was introduced into COS-7 cells by calcium phosphate-mediated transfection (20 µg/10-cm dish). Cells were exposed to the precipitate for 24 hr, after which the medium was replaced with fresh medium. Twenty-

four hours later the cells were harvested or the cAMP assay was performed.

cAMP assays. COS-7 cells were seeded into 12-well plates at a density of 10^5 cells/well. Cells were transfected as described above. Forty-eight hours later cells were washed once with phosphate-buffered saline and incubated for 15 min at 37° with $100\ \mu\text{M}$ isobutylmethylxanthine and test agents in phosphate-buffered saline. The reaction was stopped by aspiration of the medium, followed by the addition of $500\ \mu\text{l}$ of ice-cold ethanol. After 2 hr at room temperature, the ethanol fraction was collected and lyophilized. The pellet was reconstituted and cAMP was quantified using a radioimmunoassay (Immunotech radioimmunoassay kit 1117).

Radioligand binding assay. Membranes were prepared as described (23). [³H]5-HT saturation and competition binding experiments were performed with 10–20 μg of protein/sample, in a final volume of 500 μl of 50 mM Tris·HCl, pH 7.4, 4 mM CaCl₂, at 37° for 20 min. Reactions were terminated by vacuum filtration over Whatman GF/B glass fiber filters, which were then rinsed four times with 4 ml of 50 mM Tris·HCl, pH 7.4. Nonspecific binding was defined with 10 μM 5-HT.

PCR analysis. To perform PCR analysis we used the following oligonucleotides: (i) CCGACAGAATCATTTTTGGCCATAC and (ii) GAGCAGATCAACTATGGCAGAGTC, corresponding to positions 733 and 331, respectively (Fig. 1). One microgram of total RNA from various organs was reverse transcribed with 5 units of avian myeloblastosis virus reverse transcriptase (Pharmacia) and 300 ng of oligonucleotide i for 45 min at 42°. One fifth of that reaction was amplified in the presence of 5 units of *T. aquaticus* polymerase (Cetus) and 500 ng of oligonucleotides i and ii for 20 cycles. These PCR products were transferred to filters and hybridized with the *EcoRI-XhoI* cDNA probe. This fragment was ³²P-labeled by random priming and was hybridized to the filter at high stringency (42°, 50% formamide, 5× saline sodium citrate (0.75 M NaCl 175 mM sodium citrate), 1× Denhardt's solution, 200 mM sodium phosphate buffer, pH 6.5, 0.1% sodium dodecyl sulfate, 100 µg/ml tRNA). Washings were performed at high stringency (60°, 0.1× saline sodium citrate, 0.1% sodium dodecyl sulfate).

Results

The isolated mouse cDNA clone encodes a new member of the G protein-coupled receptor family. Sequence comparisons of serotonin receptors have revealed a striking amino acid sequence conservation, particularly in certain putative transmembrane domains such as domains III, VI, and VII. We therefore decided to use degenerate oligonucleotides corresponding to these regions to perform a series of reverse PCR experiments on RNA extracted from mouse colliculi neurons. The resulting fragments were subcloned and sequenced. One of these fragments was used to screen a mouse brain cDNA library. We obtained a phage recombinant that contained a 3.2-kilobase cDNA insert. Sequence analysis revealed one long open reading frame (448 amino acids) (Fig. 1). Hydropathy analysis of the predicted protein revealed seven hydrophobic domains (numbered I to VII in Fig. 1), a feature shared by all other cloned members of the G protein-coupled receptor family. The amino-terminal end displayed two putative sites for *N*-linked glycosylation and the presumed cytoplasmic domains contained consensus sites for phosphorylation by protein kinases C and A (Fig. 1), features that are found in most members of that family.

Amino acid sequence comparisons revealed homologies with G protein-coupled receptors in the putative transmembrane domains and short connecting loops but not in the amino- and carboxyl-terminal ends or in the third cytoplasmic loop, which are very variable in sequence and in length within this gene




Fig. 4. 5-HT-induced increase in cAMP levels in COS-7 cells expressing the 5-HT₁ receptor and the effect of agonists and antagonists. COS-7 cells were transfected and cAMP levels were determined as described in Materials and Methods. *Left*, effect of various concentrations of 5-HT, 5-CT, 5-MeOT, and RU 24969. cAMP levels were expressed as a percentage of the value obtained with 10 μ M 5-HT. Typically, 10 μ M 5-HT yielded an 8-fold increase in cAMP levels (from 0.25 to 2.0 pmol/10⁶ cells). *Right*, antagonist effect of methysergide, clozapine, (+)-butaclamol, and spiperone on cAMP levels induced by 100 nM 5-HT. cAMP levels were expressed as a percentage of the values obtained with 100 nM 5-HT. Data are representative of at least two independent experiments, with each point being measured in triplicate.

TABLE 1

Pharmacological profile of the 5-HT₁ receptor

Binding data correspond to competition for [³H]5-HT binding to membranes of COS-7 cells transiently expressing the 5-HT₁ receptor. IC₅₀ values required to displace 50% of [³H]5-HT binding were determined experimentally and converted to pK_d values according to the equation $K_d = IC_{50}/(1 + C/K_d)$, where C is the [³H]5-HT concentration (2 nM) and K_d is the equilibrium dissociation constant of [³H]5-HT. cAMP experiments were performed as described in Materials and Methods and in the legend to Fig. 4. 2-Bromo-LSD, bromocriptine, dihydroergocryptine (DHC), buspirone, and TFMPP behaved as antagonists but not as agonists at 10 μ M. EC₅₀ values were determined experimentally and correspond to the concentrations of agonists required to obtain a half-maximal stimulation of adenylate cyclase. The efficacy of agonists corresponds to the maximal stimulation of adenylate cyclase, and values are expressed as a percentage of the value obtained with 10 μ M 5-HT. The concentrations of antagonists required to obtain a half-maximal inhibition of 5-HT-induced cAMP levels (IC₅₀) were determined experimentally and converted to pK_i values according to the equation $K_i = IC_{50}/(1 + C/K_d)$, where C is the 5-HT concentration (100 nM) and K_d is the EC₅₀ value for 5-HT (45 nM). The presented data are representative of at least two independent experiments with each point being measured in triplicate.

Agonist	Binding, pK _d	Cyclase stimulation, pEC ₅₀	Efficacy, %	Antagonists	Binding, pK _i	Cyclase stimulation, pK _i
5-CT	9.0	8.3	91	Methiothepin	8.2	7.7
5-HT	8.3	7.3	100	2-Bromo-LSD	8.0	
5-MeOT	8.2	7.7	89	Methysergide	7.9	8.2
Bufotenine	7.0	6.3	92	Mesulergine	7.6	7.6
RU 24969	6.9	6.7	54	Metergoline	7.5	7.6
8-OH-DPAT	6.6	6.1	95	(+)-Butaclamol	7.5	7.5
Cisapride	5.8	<5		Clozapine	7.4	7.7
Sumatriptan	5.7	<5		Ergotamine	7.3	7.7
Dopamine	4.7	<5		Spiperone	7.2	7.2
DOI*	4.6	<5		DHC	7.0	
(-) Norepinephrine	3.8			Mianserin	7.0	
				Bromocriptins	6.9	
				Ketanserin	6.4	6.4
				Amitriptyline	6.4	
				Buspirone	6.4	
				Haloperidol	6.3	5.3
				TFMPP	6.3	
				Chlorpromazine	5.3	
				(-) Butaclamol	4.8	
				(-) Pindolol	4.7	<5
				(-) Propranolol	4.7	
				Remoxipride	<4	

* DOI, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane.

family. Percentages of homology were therefore calculated over the conserved regions (Fig. 2) and were used to establish a dendrogram (Fig. 3B). The percentages of homology with other known receptors are low (Fig. 3A), with the best score being 42% with the *Drosophila* serotonin receptor 5-HT_{1D}. The next closest receptors are the 5-HT_{1B}, 5-HT_{1D}, and 5-HT_{1E} serotonergic receptors (36%).

The 5-HT₁ receptor is positively coupled to adenylate cyclase. To determine whether our cDNA clone encoded a functional receptor, we introduced it into a eukaryotic expression vector and transfected COS-7 cells with the resulting recombinant. Serotonin induced an increase in cAMP levels that was dose dependent and saturable (EC₅₀ = 45 nM) (Fig.

4). In a control experiment, serotonin had no effect on cAMP levels in nontransfected COS-7 cells. This result suggests that we have isolated a 5-HT receptor that is positively coupled to adenylate cyclase. To characterize this new receptor we analyzed cAMP levels in response to a number of serotonergic agonists and antagonists. 5-CT, a 5-HT₁ agonist, was the most efficient compound at increasing cAMP levels in COS-7 cells transiently expressing the 5-HT₁ receptor. The rank order of potencies of serotonergic agonists was as follows: 5-CT > 5-MeOT > 5-HT > RU 24969 > bufotenine > 8-OH-DPAT (Fig. 4; Table 1). Sumatriptan, TFMPP, buspirone, and (-)-pindolol were inactive. We also tested the ability of various serotonergic drugs to antagonize the stimulatory activity of 5-HT. Methio-




Fig. 5. Saturation isotherm of [^3H]5-HT binding to membranes of COS-7 cells expressing the 5-HT $_x$ receptor. Membranes were incubated with concentrations of [^3H]5-HT ranging from 0.1 nM to 20 nM, with or without 10 μM 5-HT. Specific binding is represented. *Inset*, Scatchard analysis of [^3H]5-HT binding ($K_d = 3.6$ nM, $B_{\text{max}} = 6.9$ pmol of receptor/mg of membrane protein). Data are representative of three independent experiments, with each point being measured in triplicate.

thepin, methysergide, and ergotamine, which are nonspecific 5-HT antagonists, and mesulergine, which is a 5-HT $_{1C}$ /5-HT $_2$ antagonist, were the most efficient compounds at decreasing cAMP levels (Fig. 4; Table 1). Spiperone, a 5-HT $_{1A}$ /5-HT $_2$ antagonist, was active and ketanserin, a 5-HT $_2$ antagonist, was weakly active. The 5-HT $_{1A}$ agonist 8-OH-DPAT was a weak agonist at the 5-HT $_x$ receptor but (–)-pindolol, a 5-HT $_{1A}$ antagonist, was inactive. The 5-HT $_4$ agonist cisapride had no effect on the 5-HT $_x$ receptor. The 5-HT $_x$ receptor differs also from the 5-HT $_4$ receptor in its high affinity for methiothepin, mesulergine, metergoline, and spiperone, which are all inactive at the 5-HT $_4$ receptor (19). The profile for these agonists and antagonists does not correspond to the profile of any classical 5-HT receptor subtype. Interestingly, two neuroleptics, (+)-butaclamol and clozapine, were efficient antagonists of the 5-HT $_x$ receptor.

The 5-HT $_x$ receptor displays a high affinity for [^3H]5-HT. To further characterize the 5-HT $_x$ receptor we performed binding assays on membranes of COS-7 cells transiently expressing the 5-HT $_x$ receptor. [^3H]5-HT displayed a single saturable binding site in membranes of transfected cells, whereas no specific binding was found in membranes of nontransfected cells ($K_d = 3.6$ nM and $B_{\text{max}} = 6.9$ pmol/mg of membrane

protein) (Fig. 5). [^3H]5-HT binding was displaced by a number of drugs, with the following order of potencies: 5-CT > 5-HT = 5-MeOT = methiothepin > 2-bromo-LSD > methysergide > mesulergine > (+)-butaclamol = clozapine > spiperone > RU 24969 > 8-OH-DPAT (Table 1). This pharmacological profile is atypical, because the 5-HT $_x$ receptor has a high affinity both for 5-HT $_1$ ligands such as 5-CT and for 5-HT $_2$ /5-HT $_{1C}$ ligands such as mesulergine. 5-CT, 5-HT, 5-MeOT, bufotenin, and 8-OH-DPAT, which are all agonists of the 5-HT $_x$ receptor, were more potent at displacing [^3H]5-HT than at stimulating adenylate cyclase. In contrast, in the case of antagonists the pK $_i$ values obtained in the binding experiments were similar to those obtained in the cAMP experiments. Such a difference of behavior between agonists and antagonists has often been observed with G protein-coupled receptors and suggests that [^3H]5-HT might label the high affinity state of the 5-HT $_x$ receptor. However, we have not been able to confirm this hypothesis thus far, because Gpp(NH)p had little or no effect on [^3H]5-HT binding (data not shown).

The 5-HT $_x$ receptor is expressed in the central nervous system as well as in intestine and heart. Expression of the 5-HT $_x$ transcripts was analyzed by Northern analyses and reverse PCR experiments. The Northern analysis performed on poly(A) $^+$ RNA samples extracted from various adult mouse tissues (brain, heart, kidney, lung, liver, and intestine) did not reveal any transcripts in these organs (data not shown). Because the 5-HT $_x$ cDNA had been isolated from a mouse brain cDNA library the corresponding mRNA was likely to be found in brain. To detect this mRNA we used a more sensitive technique, reverse PCR, which was performed on total RNA from various organs and which yielded a specific 404-bp fragment (see Materials and Methods and Fig. 6). The strongest signal was detected in brainstem. A weaker signal was found in forebrain, cerebellum, and embryonal colliculi neurons. In peripheral organs, a weak signal was detected in intestine and heart. In a control experiment, no bands could be detected when reverse transcriptase was omitted, indicating that the signal we observe corresponds to mRNA and not to contaminant genomic DNA.

Discussion

We have isolated a novel 5-HT receptor that is positively coupled to adenylate cyclase. The amino acid sequence of this

FOREBRAIN
BRAIN STEM
CEREBELLUM
COLLICULI
INTESTINE
SPLEEN
LIVER
KIDNEY
LUNG
HEART



Fig. 6. Distribution of 5-HT $_x$ transcripts. PCR analysis was performed with 1 μg of total RNA from various organs, as described in Materials and Methods. The specific 404-bp PCR product corresponds to the 5-HT $_x$ mRNA.

receptor is not closely related to that of any other mammalian serotonin receptor. The nearest relative of the 5-HT₂ receptor is the *Drosophila* 5-HT_{dro1} receptor, which is also coupled positively to adenylate cyclase. The resemblance between these receptors might therefore be related to their common coupling to second messengers. A similar situation was found in the 5-HT₁ and 5-HT₂ families, which can be distinguished by their interactions with second messengers. All of the members of the 5-HT₁ family, including the mammalian 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1D}, 5-HT_{1E}, and 5-HT_{1F} receptors, as well as two *Drosophila* receptors, 5-HT_{dro2A} and 5-HT_{dro2B}, are negatively coupled to adenylate cyclase. Similarly, all members of the 5-HT₂ family, such as the 5-HT_{2A}, 5-HT_{2C}, and recently cloned stomach fundus 5-HT_{2F} receptors, activate phospholipase C. The existence in both vertebrates and invertebrates of families of 5-HT receptors with distinct intracellular signaling properties suggests that these families appeared early in evolution and that they might play distinct fundamental roles in all nervous systems.

To obtain insights into the possible physiological roles of the 5-HT₂ receptor, we have tried to relate it to receptors with similar properties that have already been reported. Unfortunately, few 5-HT receptors positively coupled to adenylate cyclase and expressed in the central nervous system have been characterized in sufficient detail to allow a meaningful comparison with the 5-HT₂ receptor. These receptors include the 5-HT₄ receptor expressed in embryonal colliculi neurons and in hippocampus (19) and a 5-HT_{1A}-like receptor expressed in hippocampus (24, 25). Compared with the 5-HT_{1A} receptor, the 5-HT₂ receptor has a lower affinity for 8-OH-DPAT and spiperone and a higher affinity for mesulergine and clozapine. Concerning the 5-HT₄ receptor, there is even less resemblance. The 5-HT₂ receptor has a much higher affinity for 5-CT, 8-OH-DPAT, RU 24969, spiperone, methiothepin, and mesulergine than does the 5-HT₄ receptor. The 5-HT₂ receptor also does not correspond to a number of other stimulatory 5-HT receptors such as those found in NCB20 cells (26) and in pulmonary artery smooth muscle cells (27). In addition, the 5-HT₂ receptor differs markedly from a recently cloned 5-HT receptor that is also positively coupled to adenylate cyclase and that has been tentatively named 5-HT₆ (21). Although the amino acid sequence of the 5-HT₂ receptor is related most closely to that of the 5-HT_{dro1} receptor and to a lesser extent to those of members of the 5-HT₁ family, the 5-HT₆ receptor does not resemble any other 5-HT receptor (Fig. 3). Unlike the 5-HT₂ receptor, the 5-HT₆ receptor has a low affinity for 5-CT and mesulergine (21). There are a number of additional cases where 5-HT-sensitive adenylate cyclases have been reported, such as in cortex (28), hypothalamus, and spinal cord (29, 30), but the pharmacological profiles of these activities have not been established with enough compounds to allow a comparison with the 5-HT₂ receptor. In the cardiovascular and gastrointestinal systems, there are also reports of 5-HT₁-like receptors stimulating adenylate cyclase (31). In particular, 5-CT has been shown to mediate relaxation and elevation of cAMP in the porcine vena cava (32). In addition, a 5-HT₁-like receptor that induces tachycardia in isolated cat hearts displays a pharmacological profile that is similar to the profile of the 5-HT₂ receptor (33–35). In both cases, agonists and antagonists display the same rank order of potencies; 5-CT is the most efficient agonist, whereas methiothepin is the strongest antagonist. This receptor might correspond to the 5-HT₂ receptor, because we

could detect 5-HT₂ mRNA in heart. Another receptor that might be related to the 5-HT₂ receptor induces relaxation in guinea pig ileum and is labeled by ¹²⁵I-LSD (36). The order of potency of agonists is 5-CT > 5-HT > 8-OH-DPAT = RU 24969, whereas the order of potencies of antagonists is metergoline = mesulergine > spiperone > haloperidol. Such a profile, where metergoline, mesulergine, and spiperone display similar high potencies (8 > pK_i > 7), does not correspond to that of any of the classic 5-HT subtypes. Again, the fact that we found 5-HT₂ mRNA in intestine makes it a good candidate for the 5-HT receptor that relaxes the guinea pig ileum.

Interestingly, a number of therapeutically important drugs, such as the typical antipsychotic drugs butaclamol and spiperone and the atypical antipsychotic agent clozapine, have a high affinity for the 5-HT₂ receptor. These drugs are believed to exert their therapeutic effects by interacting mainly with D₂ dopaminergic receptors. However, atypical effects of clozapine such as a reduced incidence of extrapyramidal side effects have been suggested to be mediated by D₄ receptors or 5-HT₂ receptors, both of which have a higher affinity for clozapine than do D₂ receptors (37). The high affinity of clozapine for the 5-HT₂ receptor and the fact that this receptor is expressed in the brain makes this receptor an additional candidate to explain some of the atypical effects of clozapine. A more precise localization of the sites of expression of the 5-HT₂ receptor might allow us to further document this idea. In addition, the availability of the 5-HT₂ gene should allow us to alter the expression of the 5-HT₂ receptor *in vivo* and to study the consequences of such alterations for physiology and behavior.

Acknowledgments

We are grateful to A. Dumuis and J. Bockaert for the gift of mouse embryonal colliculi neurons. We acknowledge A. Staub and F. Ruffenach for oligonucleotide synthesis, as well as E. Raucher, J. M. Lafontaine, B. Boulay, S. Metz, and C. Werlé for help in preparing the manuscript. For helpful comments and valuable discussions we thank U. Boschert, A. Ghavami, R. Grailhe, H. Matthes, S. Ramboz, F. Saudou, and C. Mendelsohn.

References

1. Wilkinson, L. O., and C. T. Dourish. Serotonin and animal behaviour, in *Serotonin Receptor Subtypes: Basic and Clinical Aspects* (S. J. Peroutka, ed.). Wiley-Liss, New York, 147–210 (1991).
2. Sleight, A. J., P. A. Pierce, A. W. Schmidt, C. R. Hekmatpanah, and S. J. Peroutka. The clinical utility of serotonin receptor active agents in neuropsychiatric disease, in *Serotonin Receptor Subtypes: Basic and Clinical Aspects* (S. J. Peroutka, ed.). Wiley-Liss, New York, 211–227 (1991).
3. Hen, R. Of mice and flies: commonalities among 5-HT receptors. *Trends Pharmacol. Sci.* 13:160–165 (1992).
4. Zifa, E., and G. Fillion. 5-Hydroxytryptamine receptors. *Pharmacol. Rev.* 44:401–458 (1992).
5. Fargin, A., J. R. Raymond, M. J. Lohse, B. K. Kobilka, M. G. Caron, and R. J. Lefkowitz. The genomic clone G-21 which resembles the β -adrenergic receptor sequence encodes the 5-HT_{1A} receptor. *Nature (Lond.)* 335:358–360 (1988).
6. Voigt, M. M., D. J. Laurie, P. H. Seeburg, and A. Bach. Molecular cloning and characterization of a rat brain cDNA encoding a 5-hydroxytryptamine_{1B} receptor. *EMBO J.* 10:4017–4023 (1991).
7. Maroteaux, L., F. Saudou, N. Amlaiky, U. Boschert, J. L. Plassat, and R. Hen. The mouse 5HT1B receptor: cloning, functional expression and localization in motor control centers. *Proc. Natl. Acad. Sci. USA* 89:3020–3024 (1992).
8. Hartig, P. R., T. A. Branchek, and R. L. Weinshank. A subfamily of 5-HT_{1D} receptor genes. *Trends Pharmacol. Sci.* 13:152–159 (1992).
9. McAllister, G., A. Charlesworth, C. Snodin, M. S. Beer, A. J. Noble, D. N. Middlemiss, L. L. Iversen, and P. Whiting. Molecular cloning of a serotonin receptor from human brain (5-HT_{1B}): a fifth 5-HT₁-like subtype. *Proc. Natl. Acad. Sci. USA* 89:5517–5521 (1992).
10. Zgombick, J. M., L. E. Schechter, M. Macchi, P. R. Hartig, T. Branchek, and R. L. Weinshank. Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine_{1B} receptor. *Mol. Pharmacol.* 42:1036–1042 (1992).
11. Amlaiky, N., S. Ramboz, U. Boschert, J. L. Plassat, and R. Hen. Isolation of a mouse "5HT1E like" serotonin receptor expressed predominantly in hippocampus. *J. Biol. Chem.* 267:19761–19765 (1992).

12. Adham, N., H.-T. Kao, L. E. Schechter, J. Bard, M. Olsen, D. Urquhart, M. Durkin, P. R. Hartig, R. L. Weinshank, and T. Branchek. Cloning of another human serotonin receptor (5-HT_{1F}): a fifth 5-HT₁ receptor subtype coupled to inhibition of adenylate cyclase. *Proc. Natl. Acad. Sci. USA* 90:408-412 (1993).
13. Pritchett, D. B., A. W. J. Bach, M. Wozney, O. Taleb, R. Dal Toso, J. C. Shih, and P. H. Seeburg. Structure and functional expression of cloned rat serotonin 5-HT₁ receptor. *EMBO J.* 7:4135-4140 (1988).
14. Julius, D., A. B. MacDermott, R. Axel, and T. M. Jessel. Molecular characterization of a functional cDNA encoding the serotonin 1C receptor. *Science (Washington D. C.)* 241:558-564 (1988).
15. Fouget, M., D. Hoyer, L. A. Pardo, A. Parekh, F. W. Kluxen, H. O. Kalkman, W. Stühme, and H. Lübbert. Cloning and functional characterization of the rat stomach fundus serotonin receptor. *EMBO J.* 11:3481-3487 (1992).
16. Plassat, J. L., U. Boschert, N. Amlaiky, and R. Hen. The mouse 5HT₁ receptor reveals a remarkable heterogeneity within the 5-HT_{1D} receptor family. *EMBO J.* 11:4779-4786 (1992).
17. Matthes, H., U. Boschert, N. Amlaiky, R. Grailhe, J. L. Plassat, F. Muscatelli, M. G. Mattei, and R. Hen. The mouse 5-HT_{1A} and 5-HT_{1B} receptors define a new family of serotonin receptors: cloning, functional expression and chromosomal localization. *Mol. Pharmacol.* 43:313-319 (1993).
18. Cornfield, L. J., and D. L. Nelson. Biochemistry of 5-hydroxytryptamine receptor subtypes: coupling to second messenger systems, in *Serotonin Receptor Subtypes: Basic and Clinical Aspects* (S. J. Peroutka, ed.). Wiley-Liss, New York, 81-102 (1991).
19. Bockaert, J., J. Fozard, A. Dumuis, and D. E. Clarke. The 5-HT₁ receptor: a place in the sun. *Trends Pharmacol. Sci.* 13:141-145 (1992).
20. Witz, P., N. Amlaiky, J. L. Plassat, L. Maroteaux, E. Borrelli, and R. Hen. Cloning and characterization of a *Drosophila* serotonin receptor that activates adenylate cyclase. *Proc. Natl. Acad. Sci. USA* 87:8940-8944 (1990).
21. Monsma, F. J., Y. Shen, R. P. Ward, M. W. Hamblin, and D. R. Sibley. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. *Mol. Pharmacol.* 43:320-327 (1993).
22. Green, S., I. Isseman, and E. Sheer. A versatile *in vivo* and *in vitro* eukaryotic expression vector for protein engineering. *Nucleic Acids Res.* 16:369-370 (1988).
23. Amlaiky, N., and M. G. Caron. Photoaffinity labeling of the D2-dopamine receptor using a novel high affinity radioiodinated probe. *J. Biol. Chem.* 260:1983-1986 (1985).
24. Markstein, R., D. Hoyer, and G. Engel. 5-HT_{1A} receptors mediate stimulation of adenylate cyclase in rat hippocampus. *Naunyn-Schmiedeberg Arch. Pharmacol.* 333:335-341 (1986).
25. Shenker, A., S. Maayani, H. Weinstein, and J. P. Green. Pharmacological characterization of two 5-hydroxytryptamine receptors coupled to adenylate cyclase in guinea pig hippocampal membranes. *Mol. Pharmacol.* 31:357-367 (1987).
26. Conner, D. A., and T. E. Mansour. Serotonin receptor-mediated activation of adenylate cyclase in the neuroblastoma NCB20: a novel 5-hydroxytryptamine receptor. *Mol. Pharmacol.* 37:742-751 (1990).
27. Becker, B. N., T. W. Gettys, J. P. Middleton, C. L. Olsen, F. J. Albers, S. L. Lee, L. Fanburg, and J. R. Raymond. 8-Hydroxy-2-(di-*n*-propylamino)tetralin-responsive 5-hydroxytryptamine₁-like receptor expressed in bovine pulmonary artery smooth muscle cells. *Mol. Pharmacol.* 42:817-825 (1992).
28. Ahn, H. S., and M. H. Makman. Serotonin sensitive adenylate cyclase activity in monkey anterior limbic cortex: antagonism by molindone and other antipsychotic drugs. *Life Sci.* 23:507-512 (1978).
29. Daszuta, A., F. Pons, and J. Cadilhac. Effect of serotonin on cyclic AMP level in rat hypothalamus slices during development. *Eur. J. Pharmacol.* 56:397-401 (1979).
30. Enjalbert, A., S. Bourgoin, M. Hamon, J. Adrien, and J. Bockaert. Postsynaptic serotonin-sensitive adenylate cyclase in the central nervous system: development and distribution of serotonin-sensitive adenylate cyclases in rat and guinea pig brain. *Mol. Pharmacol.* 14:2-10 (1977).
31. Luchins, A. R., and M. H. Makman. Presence of histamine and serotonin receptors associated with adenylate cyclase in cultured calf-aorta smooth muscle cells. *Biochem. Pharmacol.* 29:3155-3161 (1980).
32. Trevethick, M. A., W. Feniuk, and P. P. A. Humphrey. 5-Carboxamidotryptamine: a potent agonist mediating relaxation and elevation of cAMP in the isolated neonatal porcine vena cava. *Life Sci.* 38:1521-1528 (1986).
33. Connor, H. E., W. Feniuk, P. P. A. Humphrey, and M. J. Perren. 5-Carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats. *Br. J. Pharmacol.* 87:417-426 (1986).
34. Saxena, P. R., E. J. Mylecharane, and J. Heiligers. Analysis of the heart rate effects of 5-hydroxytryptamine in the cat: mediation of tachycardia by 5-HT₁-like receptors. *Naunyn-Schmiedeberg Arch. Pharmacol.* 330:121-129 (1985).
35. Saxena, P. R., and C. M. Villalon. Cardiovascular effects of serotonin agonists and antagonists. *J. Cardiovasc. Pharmacol.* 15:S17-S34 (1990).
36. Kalkman, H. O., G. Engel, and D. Hoyer. Inhibition of 5-carboxamidotryptamine-induced relaxation of guinea-pig ileum correlates with [¹²⁵I]LSD binding. *Eur. J. Pharmacol.* 129:139-145 (1986).
37. Meltzer, H. Y., and G. A. Gudelsky. Dopaminergic and serotonergic effects of clozapine. *Arzneim.-Forsch. Drug Res.* 42:268-272 (1992).
38. Saudou, F., U. Boschert, N. Amlaiky, J. L. Plassat, and R. Hen. A family of *Drosophila* serotonin receptors with distinct intracellular signalling properties and expression patterns. *EMBO J.* 11:7-17 (1992).
39. Higgins, D. G., and P. M. Sharp. CLUSTAL: a package for performing multiple sequence alignments on a microcomputer. *Gene* 73:237-244 (1988).

Send reprint requests to: René Hen, Laboratoire de Génétique Moléculaire des Eucaryotes du CNRS, U/184 de l'INSERM, Département de Neurobiologie, Faculté de Médecine, 11 rue Humann, 67085 Strasbourg Cedex, France.